230 related articles for article (PubMed ID: 32067259)
21. First Extensive Analysis of
Louarn N; Galicier L; Bertinchamp R; Lussato D; Montravers F; Oksenhendler É; Merlet P; Gérard L; Vercellino L
J Clin Oncol; 2022 Apr; 40(12):1346-1355. PubMed ID: 35073166
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
[TBL] [Abstract][Full Text] [Related]
23. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
24. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
25. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
[TBL] [Abstract][Full Text] [Related]
26. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
[TBL] [Abstract][Full Text] [Related]
28. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
[TBL] [Abstract][Full Text] [Related]
29. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
30. Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment.
Triumbari EKA; Morland D; Cuccaro A; Maiolo E; Hohaus S; Annunziata S
Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292014
[TBL] [Abstract][Full Text] [Related]
31. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
32. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
33. Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.
Zaman MU; Fatima N; Zaman A; Zaman U; Zaman S; Tahseen R
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2343-2348. PubMed ID: 32856864
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
35. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
36. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
[TBL] [Abstract][Full Text] [Related]
37. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Seifert R; Kersting D; Rischpler C; Sandach P; Ferdinandus J; Fendler WP; Rahbar K; Weckesser M; Umutlu L; Hanoun C; Hüttmann A; Reinhardt HC; von Tresckow B; Herrmann K; Dührsen U; Schäfers M
Leukemia; 2022 Dec; 36(12):2845-2852. PubMed ID: 36241697
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.
Jung SH; Ahn JS; Kim YK; Kweon SS; Min JJ; Bom HS; Kim HJ; Chae YS; Moon JH; Sohn SK; Lee SW; Byun BH; Do YR; Lee JJ; Yang DH
BMC Cancer; 2015 Mar; 15():198. PubMed ID: 25879747
[TBL] [Abstract][Full Text] [Related]
39.
Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
[TBL] [Abstract][Full Text] [Related]
40. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
